Relationship of serum isoflavone, insulin and adiponectin levels with breast cancer risk
- 617 Downloads
Obesity is one of the well-known risk factors of breast cancer. Accumulating evidence suggests that adiponectin, an obesity-related hormone, is inversely associated with breast cancer risk, particularly in postmenopausal women. Obesity is also associated with high levels of insulin. In addition, studies have suggested that the soy isoflavones present in the traditional Japanese diet have been associated with decreased risk of breast cancer. However, there is no study that has assessed associations between serum levels of isoflavones, insulin, adiponectin and the risk of breast cancer all together with menopausal status.
In a case–control study of 63 histologically confirmed breast cancer patients and 76 controls, serum isoflavone, insulin, and high-molecular-weight (HMW) adiponectin levels and breast cancer risk were examined for their association with breast cancer risk after adjustment for various risk factors.
Women in the highest tertile of serum HMW adiponectin levels were associated with a statistically significant decreased risk for breast cancer compared with women in the lowest tertile [odds ratio (OR), 0.09; 95 % confidence interval (CI) 0.03–0.33]. This association was observed in postmenopausal women (OR 0.06; 95 % CI 0.01–0.28), but not in premenopausal women. The observed associations were independent of possible effects of insulin, body mass index, and known risk factors for breast cancer. Serum isoflavones and insulin levels were not associated with breast cancer risk.
This study suggests that high serum HMW adiponectin levels are significantly associated with a decreased risk for breast cancer. Our result support the hypothesis that serum adiponectin may act as a potential biomarker for breast cancer.
KeywordsIsoflavones Insulin Adiponectin Breast cancer
This study is supported by a Grant-in-aid for Scientific Research (Project Number 24659325) from the Ministry of Education, Science, Sports and Culture of Japan.
Conflict of interest
All authors have no conflict of interest.
- 7.Onozawa M, Fukuda K, Ohtani M, Akaza H, Sugimura T, Wakabayashi K. Effects of soybean isoflavones on cell growth and apoptosis of the human prostatic cancer cell line LNCaP. J Clin Oncol. 1998;28:360–3.Google Scholar
- 14.Stefan N, Vozarova B, Funahashi T, Matsuzawa Y, Weyer C, Lindsay RS, et al. Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. Diabetes. 2002;51:1884–8.CrossRefPubMedGoogle Scholar
- 42.Iwasaki M, Inoue M, Otani T, Sasazaki S, Kurahashi N, Miura T, et al. Plasma isoflavone level and subsequent risk of breast cancer among Japanese women: a nested case–control study from the Japan public health center-based prospective study group. J Clin Oncol. 2008;26:1677–83.CrossRefPubMedGoogle Scholar
- 52.Muti P, Quattrin T, Grant BJB, Krogh V, Micheli A, Schünemann HJ, et al. Fasting glucose is a risk factor for breast cancer: a prospective study. Cancer Epidemiol Biomark Prev. 2002;11:1361–8.Google Scholar
- 58.Osborne CK, Monaco ME, Lippman ME, Kahn CR. Correlation among insulin binding, degradation, and biological activity in human breast cancer cells in longterm tissue culture. Cancer Res. 1987;38:94–102.Google Scholar
- 61.Ward H, Chapelais G, Kuhnle GG, Ruben R, Khaw KT, Bingham S. European prospective into cancer-Norfolk cohort. Breast cancer risk in relation to urinary and serum biomarkers of phytoestrogen exposure in the European prospective into Cancer-Norfolk cohort study. Breast Cancer Res. 2008;10:R32.CrossRefPubMedCentralPubMedGoogle Scholar
- 67.Mohamad AS, Taher AN, Mohamad AA, El-Nasr MS. Evaluation of serum adiponectin level in Egyptian breast cancer patients before and after treatment. Med J Cairo Univ. 2010;78:67–76.Google Scholar
- 68.Pfeiler G, Konigsberg R, Hadji P, Fitzal F, Tea MKM, Vogl S, et al. The impact of estrogen depletion by aromatase inhibitors on adiponectin serum levels in postmenopausal patients with breast cancer. J Clin Oncol (meeting abstracts). 2013;31(suppl):e11601.Google Scholar